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Abstract
Aims/hypothesis Epidemiological studies have shown that diabetes is a well-established independent but modifiable risk factor
for stroke. The aim of this post hoc analysis of data from the Steno-2 Study was to examine whether multiple risk factor
intervention reduced the risk for stroke in individuals with type 2 diabetes and microalbuminuria.
Methods In the Steno-2 Study, 160 individuals with type 2 diabetes and microalbuminuria were randomised to inten-
sified or conventional multiple risk factor intervention, targeting classical cardiovascular disease risk factors for a
mean of 7.8 years, and then followed for a total mean of 21.2 years. The primary endpoint in this post hoc analysis
was time to first stroke event.
Results During follow-up, 30 participants experienced a total of 39 strokes. Individuals randomised to conventional
therapy were more likely to experience a stroke than those in the intensive-therapy group, with 29 total strokes occurring
in 21 participants (26%) in the conventional-therapy group vs a total of ten strokes in nine participants (11%) in the
intensive-therapy group (HR 0.31 [95% CI 0.14, 0.69]; p = 0.004). Also, the number of recurrent strokes was significantly
reduced with intensive therapy.
Conclusions/interpretation Intensified multiple risk factor intervention in patients with type 2 diabetes and microalbuminuria
reduces the risk for strokes as well as the number of recurrent cerebrovascular events.
Trial registration ClinicalTrials.gov NCT00320008.
Keywords Microalbuminuria . Multifactorial intervention . Stroke . Type 2 diabetes
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Abbreviations
CVD Cardiovascular disease
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Introduction
A recent publication from the Global Burden of Disease (GBD)
Study 2016 estimates the global lifetime risk of stroke to be
24.9% in the total population for both sexes, with an increase
in risk of 15.4% for men and 3.2% for women compared with
the previous survey, which was conducted in 1990 [1].
In individuals with diabetes in the USA, an increased inci-
dence of stroke from 1990 to 2010 has been demonstrated.
Although a 52.7% decrease in the age-standardised rates of
stroke was seen, the increase in diabetes prevalence resulted in
a 47% increase in the yearly number of strokes [2].
The importance of individualised intensified multifactorial
intervention in the treatment of type 2 diabetes has been
highlighted in the Steno-2 Study. In this study, an increased
median lifespan of 7.9 years with significant risk reductions for
major cardiovascular disease (CVD) events, heart failure and
microvascular complications was observedwith intensified treat-
ment of multiple risk factors vs conventional therapy [3]. Also, it
has been demonstrated that these results were achieved at no
extra cost; the total direct cost of the intensified multifactorial
intervention was similar to that of conventional treatment [4].
In the present post hoc analysis, the primary aim was to
examine the difference in time to first stroke event between the
intensive and conventional treatment groups of the Steno-2
Study.
Methods
Study design The Steno-2 Study (ClinicalTrials.gov
registration no. NCT00320008) has been described in detail
previously [3–5]. In short, during 1992 and 1993, 160
participants with type 2 diabetes and microalbuminuria were
randomised to conventional or intensified multifactorial
treatment targeting several concomitant risk factors (n = 80
in each group; Fig. 1). Mean treatment duration was 7.8 years.
After 7.8 years, the randomised part of the study ended and all
individuals were offered intensified multifactorial treatment,
allowing the trial to continue as an observational follow-up
study for an additional 13.4 years.
The protocol for the follow-up trial in the Steno-2 Study
was conducted in accordance with the declaration of Helsinki
and approved by a local ethics committee (Ethics committee,
Capital Region of Denmark; protocol ID number: H-KA-
99035-GS, add. 41104) and by the Danish Data Protection
Agency (J.Nr. 2015-41-4042). All patients gave their in-
formed consent upon randomisation and confirmed this on
follow-up visits.
Endpoint definitions All CVD endpoints in the Steno-2 Study
were defined a priory and have been described in detail else-
where [5]. The definitions for stroke and transient ischaemic
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attack (TIA) are shown in the electronic supplementary mate-
rials (ESM) Methods. All possible cases of stroke and TIA
were adjudicated by an external committee masked for origi-
nal treatment allocation.
In the current analysis, we distinguish between stroke and
TIA. This was not the case in the original Steno-2 Studywhere
we used a combination of the two conditions in order to in-
crease power due to the shorter duration of follow-up and,
thus, a smaller number of expected events.
The primary analysis of the present study was time to first
stroke event, with the secondary analyses being time to a
combined endpoint of stroke and cardiovascular death and
time to a combined endpoint of stroke and all-cause mortality.
In sensitivity analyses, cases of TIA were added to the end-
points specified above.
Statistical analyses HRs for the primary and secondary out-
comes of this post hoc analysis were calculated using Cox
regression. Recurrent strokes were compared using Fisher’s
exact test. Statistical analyses were performed using Stata/IC
version 15 (StataCorp, College Station, TX, USA). For the
primary outcome, proportional hazards assumption was
checked by the ‘estat phtest’ function of Stata.
Results
Baseline values in each of the two original treatment groups
are shown in the ESM Table 1. During a follow-up of
21.2 years, 30 individuals experienced a total of 39 stroke
events. Participants randomised to conventional therapy were
more likely to experience a stroke, with a total of 29 strokes
occurring in 21 individuals (26%) in the conventional-therapy
group, compared with a total of ten stroke events in nine
individuals (11%) in the intensive-therapy group.
Post-trial follow-up assessment (n=56) 
Lost to follow-up: n=24
o Died: 24
Long term follow-up assessment (n=42)
Lost to follow-up: n=38 
o Died: 38
Allocated to intensive treatment (n=80)
Assessed for microvascular complications 
(n=76) 
Lost to follow-up: n=4 
o Died: 4
Assessed for macrovascular complications 
(n=67)
Lost to follow-up: n=13
o Died: 13
Post-trial follow-up assessment (n=40)
Lost to follow-up: n=40
o Died: 40
Long term follow-up assessment (n=24) 
Lost to follow-up: n=56
o Died: 55 
o Emigrated: 1
Randomised (n=160)
Allocated to conventional treatment 
(n=80)
Assessed for microvascular complications 
(n=78) 
Lost to follow-up: n=2
o Died: 2
Assessed for macrovascular complications 
(n=63)
Lost to follow-up: n=17
o Died: 17
Interventional part of study ended;
all patients offered intensive treatment in 2001
1993
2001
2006
2014
1997
Fig. 1 CONSORT diagram
showing participant flow
throughout the Steno-2 trial. The
first 7.8 years were the active
intervention period, after which
time the randomisation was
neutralised and continued as a
post-trial observational follow-up
study with all remaining
participants being offered the
same treatment as the original
intensive-therapy group. At the
time of randomisation, the mean
age was 55.1 years and 66% were
male. All participants had
microalbuminuria. Reproduced
from [8] under the terms of the
Creative Commons Attribution
4.0 International License (http://
creativecommons.org/licenses/
by/4.0/), which permits
unrestricted use, distribution and
reproduction in any medium
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The hazard for stroke was reduced by 69% with intensive
therapy vs conventional treatment (HR 0.31 [95% CI 0.14,
0.69]; p = 0.004; Fig. 2). The pattern was similar for TIA
and for the combined event of stroke and TIA (Table 1).
We also demonstrated that intensive therapy resulted in a
significantly reduced risk of the combined endpoint of stroke
and CVD mortality (n = 55; HR 0.36 [95% CI 0.20, 0.63];
p < 0.001) and for the combined endpoint of stroke and all-
cause mortality (n = 101; HR 0.46 [95% CI 0.31, 0.69;
p < 0.001) (Table 1). The median time to stroke or death was
19.9 years in the intensive-therapy group and 11.4 years in the
conventional-therapy group.
In the intensive-therapy group, 4 (11%) out of the 35 par-
ticipants with a cardiovascular event experienced a stroke as
their first manifestation of CVD, whereas this was the case in
14 out of 51 individuals (27%) in the conventional-therapy
group.
Of the total 39 strokes evaluated in the study, 35 were
ischaemic. The remaining four were haemorrhagic strokes,
two of which were the first stroke in one patient in each of
the two treatment groups, with the last two being a recurrent
stroke occurring in two different individuals in the conven-
tionally treated group.
Individuals whowere originally randomised to convention-
al treatment were more likely to experience recurrent strokes
than those originally randomised to intensified therapy, with
one participant in the intensive-therapy group vs ten partici-
pants in the conventional-therapy group experiencing more
than one stroke (p = 0.018).
A similar proportion of individuals in the two groups who
experienced a stroke died during follow-up (78% in the
conventional-therapy group vs 71% in the intensive-therapy
group). However, participants in the original intensive-therapy
group survived for a significantly shorter period after a stroke
than those originally randomised to conventional therapy (me-
dian 0.3 years vs 3.1 years, respectively). This pattern was not
observed for cardiovascular events not related to strokes
(myocardial infarctions, amputations and peripheral or cardiac
revascularisation), for which a smaller proportion of individ-
uals randomised to intensive treatment vs conventional treat-
ment died during follow-up after an event (55% vs 82%), with
no difference in survival time after the evident event (median
3.4 years vs 3.9 years).
Discussion
In the present post hoc analysis of data from individuals with
type 2 diabetes and microalbuminuria from the Steno-2 Study
with 21.2 years of follow-up, the hazard for first stroke after
randomisation was reduced by 69% and the absolute risk by
15% with intensive therapy vs conventional treatment.
Similarly, individuals originally randomised to conventional
treatment were more likely to have recurrent strokes than
those originally randomised to intensified therapy. Our find-
ings once again emphasise the importance of an intensified
multifaceted intervention approach, according to present
EASD/ADA guidelines, for reducing CVD in patients with
type 2 diabetes.
The proportion of individuals with a stroke during the
follow-up period was 11% and 26% in the intensive- and
conventional-therapy group, respectively. Since all partici-
pants in the Steno-2 Study had microalbuminuria (a marker
of general vascular damage, indicating a higher risk for future
Table 1 Number of participants
(referring to first event) and HR
with 95% CI of primary and sec-
ondary outcomes
Outcome Intensive therapy (n) Conventional therapy (n) HR (95% CI) p value
Stroke 9 21 0.31 (0.14, 0.69) 0.004
TIA 1 9 0.08 (0.01, 0.66) 0.019
Stroke or TIA 10 25 0.28 (0.13, 0.58) <0.001
Stroke + CVD death 18 37 0.36 (0.20, 0.63) <0.001
Stroke + all-cause death 40 61 0.46 (0.31, 0.69) <0.001
>1 stroke 1 10 – 0.018a
a p value calculated using Fisher’s exact test
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Fig. 2 Cumulative incidence frequency plot of time to first stroke. The
hazard for stroke was reduced by 69% in the intensive-therapy group
(p=0.004). Solid line, intensive-therapy group; dashed line, convention-
al-therapy group
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complications) at baseline, the high incidence of stroke em-
phasises the importance of early screening for vascular risk
factors in individuals with type 2 diabetes.
A surprising finding in the present post hoc analysis was
the significantly shorter median lifespan after the first stroke
of 0.3 years in the intensive-therapy group vs 3.1 years in the
conventional-therapy group. We have no conclusive explana-
tion for this finding. However, since the treatment algorithm
for intensive therapy recommended a daily intake of 150 mg
acetylsalicylic acid (ASA), it is reassuring that there was no
increase in the number of cerebral haemorrhage events in
those originally assigned to the intensive-treatment group.
In diabetic nephropathy, the classic Kimmelstiel–Wilson
lesions are nodules of hyaline material in the glomerulus that
occur due to an increase in mesangial matrix deposition [6]. In
the brain, it has been demonstrated that the small arteries and
arterioles that supply the territory of lacunar infarcts show
segmental arterial disorganisation, fibrinoid degeneration
and lipohyalinosis in those with diabetes or hypertension [7].
We have previously shown marked risk reductions for small-
vessel disease in terms of progression of diabetic nephropathy
with the intensified treatment approach used in the Steno-2
Study [3, 5]. It could, therefore, be hypothesised that this
approach mainly prevents smaller lacunar infarctions associ-
ated with cerebral small-vessel disease, while major thrombo-
embolic strokes with more severe symptoms and a poorer
prognosis are prevented to a lesser extent.
As previously mentioned, it has been reported that the risk
for stroke in individuals with type 2 diabetes has declined on a
national scale [2]. However, despite intensified treatment as
per the protocol in the Steno-2 Study, a residual risk for stroke
of more than 10% over the duration of the ~20 year follow-up
was observed. Also, due to the increasing number of individ-
uals diagnosed with diabetes and the increased lifespan of
these patients, stroke should still be considered a major per-
sonal and societal burden.
Strengths and limitations The major strength in the Steno-2
Study is the completeness of data for individuals enrolled in
the trial. Except for one individual who emigrated from
Denmark, leading to a lack of data during the observational
part of the trial, a complete track of all endpoints and hospital
admissions was available from Danish National Registers and
applied in all analyses.
One major limitation of the study is the small sample size
of 160 individuals. Another limitation is that a high-risk group
(individuals with type 2 diabetes and microalbuminuria) were
selected as the study population. Therefore, the magnitude of
risk reduction we demonstrate here might not be attributable
to a lower risk population. However, the risk reductions with
intensive therapy presented in the current post hoc analysis are
in coherence with previous cardiovascular risk reductions re-
ported in the trial, both during its interventional and
observational phase. Furthermore, since all participants were
offered intensive treatment after the randomised phase, the
effects presented may actually be an underestimation of the
true effects.
Conclusion
Our study demonstrates that stroke is a frequent and fatal
complication in individuals with type 2 diabetes and
microalbuminuria. An intensified multifactorial intervention
significantly reduced the occurrence of this outcome, as well
as the number of recurrent cerebrovascular events.
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